Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet

Journal of Virology

Volumn 70, Issue 10, 1996, Pages 7171-7181

  Tachedjian, Gilda ^a   Mellors, John ^b   Bazmi, Hengemeh ^b   Birch, Chris ^a,c   Mills, John ^a  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c FAIRFIELD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; ZIDOVUDINE;

ARTICLE; CONFORMATIONAL TRANSITION; DRUG EFFECT; DRUG EFFICACY; ENZYME CONFORMATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0029792446     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.10.7171-7181.1996     Document Type: Article

References (65)

1. Barnes, W. M. 1994. PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates. Proc. Natl. Acad. Sci. USA 91:2216-2220.
2. Bhattacharyya, G. K., and R. A. Johnson. 1977. Statistical concepts and methods. John Wiley and Sons, New York.
3. Birch, C. J., G. Tachedjian, R. R. Doherty, K. Hayes, and I. D. Gust. 1990. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J. Infect. Dis. 162: 731-734.
4. Cheeseman, S. H., D. Havlir, M. M. McLaughlin, T. C. Greenough, J. L. Sullivan, D. Hall, S. E. Hattox, S. A. Spector, D. S. Stein, M. Myers, and D. D. Richman. 1995. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 8:141-151.
5. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis. and therapy. Science 267:483-489.
6. Collier, A. C., R. W. Coombs, M. A. Fischl, P. R. Skolnik, D. Northfelt, P. Boutin, C. J. Hooper, L. D. Kaplan, P. A. Volberding, L. G. Davis, D. R. Henrard, S. Weller, and L. Corey. 1993. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann. Intern. Med. 119:786-793.
7. Crumpacker, C. S. 1992. Mechanism of action of foscarnet against viral polymerases. Am. J. Med. 92:3S-7S.
8. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, and D. D. Richman for the AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
9. Eriksson, B. F., and R. F. Schinazi. 1989. Combinations of 3′-azido-3′-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 33:663-669.
10. Erlich, K. S., M. A. Jacobson, J. E. Koehler, S. E. Follansbee, D. P. Drennan, L. Goozé, S. Safrin, and J. Mills. 1989. Foscarnet therapy for severe acyclo-vir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann. Intern. Med. 110:710-713.
11. Grob, P. M., J. C. Wu, K. A. Cohen, R. H. Ingraham, C.-K. Shih, K. D. Hargrave, T. L. McTague, and V. J. Merluzzi. 1992. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res. Hum. Retroviruses 8:145-152.
12. Gurusinghe, A. D., S. A. Land, C. Birch, C. McGavin, D. J. Hooker, G. Tachedjian, R. Doherty, and N. J. Deacon. 1995. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J. Med. Virol. 46:238-243.
13. Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of HTLV-III/ LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566.
14. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373:123-126.
15. Hooker, D. J., G. Tachedjian, A. E. Solomon, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Arnold, and N. J. Deacon. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type-1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine (AZT). Submitted for publication.
16. Hostetler, K. Y., G. D. Kini, T.-C. Chou, and D. D. Richman. 1995. 1-0-Octadecylglycero-3-phosphonoformate exhibits enhanced activity and synergy with AZT against HIV, in vitro, abstr. 1141, p. 230. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. J. Clark, X. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, A. Hizi, S. H. Hughes, and E. Arnold. 1993. Crystal structure of human immunodeficiency virus type I reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-6324.
18. Jacobson, M. A., S. Crowe, J. Levy, F. Aweeka, J. Gamberloglio, N. McManus. and J. Mills. 1988. Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J. Infect. Dis. 158:862-865.
19. Japour, A. J., S. Welles, R. T. D'Aquila, V. A. Johnson, D. D. Richman, R. W. Coombs, P. S. Reichelderfer, J. O. Kahn, C. S. Crumpacker, and D. R. Kuritzkes for the AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. 1995. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J. Infect. Dis. 171:1172-1179.
20. Kaiser, L., L. Perrin, B. Hirschel, H. Furrer, J. Von Overbeck, M. Olmari, and S. Yerly. 1995. Foscarnet decreases human immunodeficiency virus RNA. J. Infect. Dis. 172:225-227.
21. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
22. Kellam, P., C. A. B. Boucher, J. M. G. H. Tijnagel, and B. A. Larder. 1994. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J. Gen. Virol. 75:341-351.
23. Kellam, P., and B. A. Larder. 1995. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J. Virol. 69:669-674.
24. Koshida, R., L. Vrang, G. Gilljam, J. Harmenberg, B. Oberg, and B. Wahren. 1989. Inhibition of human immunodeficiency virus in vitro by combinations of 3′-azido-3′-deoxythymidine and foscarnet. Antimicrob. Agents Chemother. 33:778-780.
25. Kozal, M. J., R. W. Shafer, M. A. Winters, D. A. Katzenstein, and T. C. Merigan. 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:526-532.
26. Kuritzkes, D. R., D. Shugarts, A. Griffin, M. Bakhtiari, J. Eron, J. Quinn, M. A. Fallon, M. Rubin, and S. Benoit. 1995. Resistance to lamivudine (3TC) and zidovudine (ZDV] in a phase II comparative trial of 3TCvs ZDV vs 3TC plus ZDV. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10(Suppl. 3):S26.
27. Larder, B. A. 1992. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:2664-2669.
28. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
29. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
30. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
31. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism of sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
32. Larder, B. A., S. D. Kemp, and D. J. Purifoy. 1989. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc. Natl. Acad. Sci. USA 86:4803-4807.
33. Larder, B. A., D. J. M. Purifoy, K. L. Powell, and G. Darby. 1987. Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature (London) 327:716-717.
34. Mayers, D. L., and J. Weir. Personal communication.
35. Mellors, J. W., H. Z. Bazmi, R. F. Schinazi, B. M. Roy, Y. Hsiou, E. Arnold, J. Weir, and D. L. Mayers. 1995. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 39:1087-1092.
36. Montaner, J. S., J. Singer, M. T. Schechter, J. M. Raboud, C. Tsoukas, M. O'Shaughnessy, J. Ruedy, K. Nagai, H. Salomon, B. Spira, and M. A. Wainberg. 1993. Clinical correlates of of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS 7:189-196.
37. Myers, G., B. Korber, S. Wain-Hobson, R. F. Smith, and G. N. Pavlakis. 1993. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory, Los Alamos, N.Mex.
38. Nanni, R. G., J. Ding, A. Jacobo-Molina, S. H. Hughes, and E. Arnold. 1993. Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design. Perspect. Drug Discov. Des. 1:129-150.
39. Neate, E. V., R. C. Pringlë, J. B. M. Jowett, D. S. Healey, and I. D. Gust. 1987. Isolation of HIV from Australian patients with AIDS, AIDS related conditions and healthy antibody positive individuals. Aust. N. Z. J. Med. 17:461-466.
40. Nguyen, M. H., R. F. Schinazi, C. Shi, N. M. Goudgaon, P. M. McKenna, and J. W. Mellors. 1994. Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines. Antimicrob. Agents Chemother. 38:2409-2414.
41. Nijhuis, M., D. de Jong, R. van Leeuwen, T. de Groot, W. Keulen, R. Shuurman, and C. Boucher. 1995. The rise in HIV-1 RNA load during 3TC/AZT combination therapy is associated with the selection of viruses resistant to both 3TC and AZT. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10(Suppl. 3):S25.
42. Oberg, B. 1989. Antiviral effects of phosphonoformate (PFA. foscarnet sodium). Pharmacol. Ther. 40:213-285.
43. Ragni, M. V., D. A. Amato, M. L. LoFaro, V. DeGruttoia, C. Van Der Horst, M. E. Eyster, C. M. Kessler, G. F. Gjerset, M. Ho, D. M. Parenti, U. Dafni, S. Rasheed, J. A. Korvick, T. C. Merigan, and the AIDS Clinical Trials Group. 1995. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. Blood 85:2337-2346.
44. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type I selected during therapy. J. Virol. 68:1660-1666.
45. Rocancourt, D., C. Bonnerot, H. Jouin, M. Emerman, and J. F. Nicolas. 1990. Activation of a β-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J. Virol. 64:2660-2668.
46. Safrin, S., T. G. Berger, I. Gilson, P. R. Wolfe, C. B. Wofsy, J. Mills, and K. K. Biron. 1991. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann. Intern. Med. 115:19-21.
47. Safrin, S., C. Crumpacker, P. Chatis, R. Davis, R. Hafner, J. Rush, H. A. Kessler, B. Landry, and J. Mills. 1991. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N. Engl. J. Med. 325:551-555.
48. Sandstrom, E. G., R. E. Byington, J. C. Kaplan, and M. S. Hirsch. 1985. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet i: 1480-1482.
49. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
50. Shafer, R. W., A. K. N. Iversen, M. A. Winters, E. Aguiniga, D. A. Katzenstein, T. C. Merigan, and the AIDS Clinical Trials Group 143 Virology Team. 1995. Drug resistance and heterogenous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172:70-78.
51. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. N. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Fiscus, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
52. Shirasaka, T., M. F. Kavlick, T. Ueno, W.-Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
53. Starnes, M. C., and Y. C. Cheng. 1988. Inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate. Virus Genes 2:241-251.
54. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
55. Studies, of Ocular Complications of AIDS Research Group (SOCA), AIDS Clinical Trials Group. 1992. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N. Engl. J. Med. 326:213-220.
56. Tachedjian, G. Unpublished data.
57. Tachedjian, G., D. J. Hooker, A. D. Gurusinghe, H. Bazmi, N. J. Deacon, J. Mellors, C. Birch, and J. Mills. 1995. Characteristion of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology 212:58-68.
58. Tachedjian, G., J. Hoy, K. McGavin, and C. Birch. 1994. Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient. J. Med. Virol. 42:207-211.
59. Tachedjian, G., D. Tyssen, S. Locarnini, I. Gust, and C. Birch. 1990. Investigation of topoisomerase inhibitors for activity against human immunodeficiency virus: inhibition by coumermycin A1. Antiviral Chem. Chemother. 1:131-138.
60. Tachedjian, M., J. Krywult, R. J. Moore, and A. L. M. Hodgson. 1995. Caseous lymphadenitis vaccine development: site-specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene. Vaccine 13: 1785-1792.
61. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. J. Janssen, and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243:369-387.
62. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
63. Tudor-Williams, G., M. H. St. Clair, R. E. McKinney, M. Maha, E. Walter, S. Santacroce, M. Mintz, K. O'Donnell, T. Rudoll, C. L. Vavro, E. M. Connor, and C. M. Wilfert. 1992. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 339:15-19.
64. i analogs as inhibitors of human T-lymphocyte virus type III reverse transcriptase. Antimicroh. Agents Chemother. 29:867-872.
65. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373:117-122.